Adalimumab: in Crohn's disease.

@article{Plosker2007AdalimumabIC,
  title={Adalimumab: in Crohn's disease.},
  author={Greg L. Plosker and Katherine A Lyseng-Williamson},
  journal={BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy},
  year={2007},
  volume={21 2},
  pages={125-32; discussion 133-4}
}
Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that included a total of >1400 patients. In the CLASSIC-I trial, adalimumab was significantly more effective than placebo for induction of remission in… CONTINUE READING
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…